QPPV.COM KNOWLEDGE ASSESSMENT

Article 31 Pharmacovigilance Referral: Legal Basis, Procedure and Regulatory Consequences in the EU

Test your understanding of the concepts covered by Article 31 Pharmacovigilance Referral: Legal Basis, Procedure and Regulatory Consequences in the EU.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is PRAC primarily responsible for in a pharmacovigilance Article 31 referral?

Issuing the final Commission decision Coordinating national administrative implementation Conducting the pharmacovigilance assessment, evaluating benefit-risk implications and adopting the applicable recommendation Approving all marketing authorisation variations independently of other committees

Question 2 of 10 Which combination best characterises a pharmacovigilance Article 31 referral?

A routine signal-management activity conducted exclusively by an MAH A Union-level statutory procedure arising from evaluation of pharmacovigilance data where the interests of the Union are involved A Commission procedure used only to withdraw centrally authorised medicines A national variation procedure for updating product information

Question 3 of 10 Why do the formal questions referred to PRAC matter operationally?

They define the procedural and scientific scope within which PRAC conducts its assessment They are included only for public communication and have no assessment relevance They determine the final Commission decision without committee analysis They allow the MAH to exclude evidence that is not favourable

Question 4 of 10 What is the most defensible way to handle procedural deadlines for re-examination?

Apply a standard deadline from memory to every referral Assume that the date of the PRAC recommendation is the only relevant date Check the current applicable legislation and referral-specific EMA documents for the notification and detailed-ground deadlines Allow the MAH to set its own deadline

Question 5 of 10 Which statement best reflects the relationship between an Article 31 referral and subsequent pharmacovigilance?

The referral permanently replaces routine signal management Once the Commission decision is published, no further monitoring is needed The outcome becomes part of the product lifecycle and should inform continued surveillance, risk-management activities and effectiveness monitoring Post-referral monitoring is required only if the product is withdrawn

Question 6 of 10 Which chronology best supports an auditable reconstruction of an Article 31 referral?

Date of first case only, followed by the final decision Formal referral, PRAC milestones and recommendation, CMDh or CHMP outcome, re-examination if applicable, final decision, implementation and follow-up Marketing launch, promotional review, annual report and eventual signal closure Commission publication followed by retrospective creation of the referral scope

Question 7 of 10 Which statement correctly distinguishes pharmacovigilance and non-pharmacovigilance Article 31 referrals?

PRAC is the principal scientific committee for both types Pharmacovigilance referrals arise from pharmacovigilance data and principally involve PRAC, whereas non-pharmacovigilance referrals principally follow the CHMP pathway Non-pharmacovigilance referrals are always initiated by MAHs Only non-pharmacovigilance referrals can include nationally authorised products

Question 8 of 10 Which statement best distinguishes a pharmacovigilance signal from an Article 31 referral?

A signal is a statutory Union procedure, while a referral is an internal safety classification A referral automatically proves that the signal is causal A signal is safety information warranting evaluation, whereas an Article 31 referral is a statutory regulatory procedure that may follow a significant concern There is no meaningful distinction between the two concepts

Question 9 of 10 Which party is not identified by the article as a potential initiator of an Article 31 pharmacovigilance referral?

A Member State competent authority The European Commission A marketing authorisation holder A healthcare professional acting individually

Question 10 of 10 What should a QPPV primarily demonstrate after an Article 31 referral has concluded?

That the QPPV personally made the Commission decision That the pharmacovigilance system incorporated the outcome, implementation was governed and ongoing monitoring remains appropriate That routine signal management was discontinued That all scientific uncertainty was eliminated

QPPV.com

Article 31 Pharmacovigilance Referral: Legal Basis, Procedure and Regulatory Consequences in the EU

Cookie Settings